What Is Metronomic Chemotherapy? Which Drugs Are Given Metronomically?

Why Was Metronomic Chemotherapy Developed?

The conventional oncology paradigm is to administer high-dose chemotherapy (for example, an intensive cytotoxic infusion every 3 weeks), then give the patient time for bone marrow recovery. This model is called the maximum tolerated dose (MTD) approach. It produces rapid tumor shrinkage, but also creates problems such as severe toxicity, the need for hospitalization, necessarily long treatment breaks, and survival of resistant clones under selective pressure. 

Metronomic chemotherapy (MC) , in contrast, aims to "starve" the tumor: drugs are given at much lower doses, generally orally, daily or weekly without interruption . Rather than achieving a moment of maximum cell killing, the goals are:

• Chronically suppressing neoangiogenesis (the tumor's ability to form blood vessels): cutting off the tumor's blood supply; this "antiangiogenic pressure" is one of MC's most critical mechanisms. Low-dose, continuous cyclophosphamide may lower VEGF levels and curb endothelial proliferation. 
• Reshaping the tumor microenvironment: reducing immunosuppressive regulatory T cells and making the antitumor CD8+ T-cell response more effective.
• Long-term sustainability with low toxicity: providing suppressive treatment tolerable even in frail, heavily pretreated patients with reduced bone marrow reserve. In this respect, MC is sometimes used as a chemotherapy "maintenance" strategy. 

Clinically, this approach has been studied particularly in advanced breast cancer, recurrent ovarian cancer, pancreatic cancer (advanced/metastatic), head and neck cancers, and certain highly vessel-dependent solid tumors such as some sarcomas .

Metronomic chemotherapy is more than a "palliative but active" strategy; in some settings it has significantly prolonged progression-free survival (PFS), and in combinations has even made the tumor microenvironment more responsive to immunotherapy. 

 Mechanism: Why Is "Low but Continuous" Effective?

1. Antiangiogenic Effect

Solid tumors need a new vascular network (angiogenesis) to grow beyond a certain volume. Continuous low-dose alkylating agents (e.g., oral cyclophosphamide 50 mg/day) chronically suppress endothelial cell proliferation and lower vascular endothelial growth factor (VEGF) levels. The result: the tumor's oxygen and nutrient supply is restricted. This antiangiogenic effect appears more sustainable than conventional "shock-dose" chemotherapy. 

2. Immune Microenvironment Modulation

Metronomic cyclophosphamide may reduce the population of immunosuppressive T-reg cells in the tumor bed, thereby enhancing cytotoxic T lymphocyte (CD8+) function. This has provided the theoretical basis in recent years for combining MC with immunotherapy: pembrolizumab (PD-1 blockade) + bevacizumab (anti-VEGF) + metronomic cyclophosphamide and similar combination regimens have shown clinically meaningful response rates, particularly in recurrent ovarian cancer. 

3. Cutting Off the Supply to Surviving Resistant Clones

The MTD approach includes a long break after high doses; during that interval, the most resistant tumor clones can recover with stromal support. By applying pressure "without any break," MC prevents these clones from sprouting. Mathematical models predict more stable suppression of tumor growth under continuous low dosing and, in some tumors, stable disease (SD) lasting for months. 

4. Toxicity Profile

Because each administered dose is low, overall toxicity (e.g., grade 3-4 neutropenia, mucositis, vomiting) may be milder than with conventional schedules. This offers a critical quality-of-life advantage for heavily pretreated patients with limited performance status. 

 Clinical Evidence in Solid Tumors

A. Ovarian Cancer (Epithelial, Recurrent / Platinum-Resistant)

Treatment options in recurrent, particularly platinum-resistant, ovarian cancer are limited, and toxicity often rapidly reduces quality of life. The concept of metronomic cyclophosphamide ± antiangiogenic therapy was therefore adopted early in this field.

Garcia et al., J Clin Oncol 2008: in a phase II study, patients with recurrent epithelial ovarian cancer received bevacizumab 10 mg/kg IV every 2 weeks + oral cyclophosphamide 50 mg/day . The primary endpoint was the proportion remaining progression-free at month 6. Findings:

• the 6-month progression-free survival target was meaningfully met;
• objective responses were observed (complete + partial responses);
• treatment was generally considered tolerable, with bevacizumab-related adverse effects such as hypertension and proteinuria being the predominant toxicities.

This is considered among the first studies to strongly demonstrate the clinical value of "continuously suppress angiogenesis + challenge the tumor with low doses." 

Zsiros et al., JAMA Oncol 2021: in a phase II, single-arm study, patients with recurrent ovarian cancer received pembrolizumab 200 mg IV q3w + bevacizumab 15 mg/kg IV q3w + continuous oral cyclophosphamide 50 mg/day . Results:

• Objective response rate (ORR): 47.5%
• Clinical benefit (complete response + partial response + stable disease ≥ 3 months): 95%
• Median progression-free survival (PFS): 10.0 months
• The adverse effect profile was clearly manageable; the most serious toxicities were hypertension (15% grade 3-4) and lymphopenia (7.5%)

This study showed that MC could be used not just alone, but synergistically with anti-VEGF therapy and immunotherapy and could serve as chronic suppressive treatment without compromising quality of life in recurrent ovarian cancer. 

Real-world data (2024): retrospective analyses published in 2024 (especially involving elderly, heavily pretreated patients with limited performance status) reported a "clinical benefit rate" (complete + partial response + ≥3 months of stable disease) of approximately 40–50% with daily oral metronomic cyclophosphamide, median PFS extending to around ~7 months, and generally manageable toxicity. 

Clinical significance: in platinum-resistant / heavily pretreated ovarian cancer, MC alone is not "curative"; however, it is increasingly considered an oral, home-administered, low-toxicity disease suppression / maintenance strategy. Combinations with bevacizumab and/or immunotherapy are particularly promising.

B. Metastatic Breast Cancer

Metronomic cyclophosphamide + methotrexate +/- bevacizumab regimens have long been studied in metastatic breast cancer. The aim is to provide nonaggressive but sustained suppression, delaying progression while preserving quality of life.

Mayer et al., randomized phase II (2024 update): in patients with metastatic breast cancer, metronomic cyclophosphamide + methotrexate was compared with the same regimen with bevacizumab added . Adding bevacizumab significantly prolonged progression-free survival, but no clear difference in overall survival was found. This supports stronger tumor suppression at the microvascular level with anti-VEGF addition. 

Older but influential studies (Colleoni et al., 2002-2006; Khan 2011) showed clinical benefit rates around 30-40% with metronomic cyclophosphamide + methotrexate ± a COX-2 inhibitor (celecoxib), meaning disease could be kept stable for at least 6 months in more than a third of patients.

In breast cancer, MC appears particularly meaningful for the following patients: those who have exhausted hormonal options, have limited responses to targeted therapies and fragile bone marrow reserve, but whom we do not want to leave completely untreated. The goal is therefore less aggressive tumor shrinkage than controlled chronic disease management.

C. Pancreatic Cancer (mPDA / Metastatic Pancreatic Ductal Adenocarcinoma)

Therapeutic options are very limited in pancreatic ductal adenocarcinoma (mPDA) progressing after standard treatment. Recently reported observational analyses described patients who remained stable after at least ~6 months of first-line chemotherapy receiving oral metronomic cyclophosphamide-based maintenance with longer progression-free survival (PFS) and overall survival (OS), and "low-profile" toxicity. Significantly longer PFS and OS were reported in mPDA patients with this approach.

These data are not yet mature at the randomized phase III level; however, they have begun to substantially change the discussion in pancreatic cancer: "should we take a chemotherapy break, or continue with mild suppression?"

D. Other Solid Tumors

For head and neck squamous cell cancers, soft tissue sarcomas, glioblastoma, and pediatric solid tumors (such as neuroblastoma), MC is being studied alongside antiangiogenic, immunomodulatory, and drug repurposing approaches. However, these areas are dominated either by pediatric data (reports of meaningful stabilization with combination MC regimens in pediatric extracranial solid tumors) or by very early phase I/II studies that do not yet shape standard practice.

Practical Application: Which Drugs, and How?

Metronomic chemotherapy is not a "single protocol"; it is a dosing philosophy. The most common components are:

• Cyclophosphamide (oral, usually 50 mg/day or 50 mg/day for 14 days on / 7 days off): the most common agent. Used in ovarian, breast, pancreatic, and certain sarcoma settings. 
• Methotrexate (low weekly doses): combined with cyclophosphamide as "CM" (cyclophosphamide-methotrexate), particularly in metastatic breast cancer. 
• Anti-VEGF agents (e.g., bevacizumab): synergistically enhance antiangiogenic suppression. A contribution particularly to PFS has been shown in ovarian and breast cancer data.  
• Immunotherapy (e.g., pembrolizumab): combined with MC, it may make the tumor microenvironment more "vulnerable to attack"; an ORR of 47.5% was reported in ovarian cancer. 

Dose-Dense ≠ Metronomic:
dose-dense chemotherapy shortens intervals (such as every 2 weeks) but maintains high doses. Metronomic treatment does the opposite: it lowers the dose but never interrupts dosing. The biological goals and toxicity profiles of the two strategies are entirely different.

Patient Selection

• Moderate / borderline performance status (ECOG 1-2): patients who would struggle to tolerate high toxicity.
• Minimal measurable disease remaining after polychemotherapy: aims to suppress microscopic residual burden.
• Patients with "exhausted options," such as platinum-resistant or heavily pretreated ovarian cancer: the goal here is stabilization without impairing quality of life.
• Patients in whom synergy with immunotherapy is expected: situations where T-reg suppression is desired.

Conversely, MC is generally unsuitable for patients with very rapid progression and a visceral crisis ; such cases require regimens that reduce tumor burden more quickly.

 Toxicity, Monitoring, and Limitations

Although MC is generally described as having "milder" toxicity, this does not mean no toxicity. Particularly with continuous oral cyclophosphamide:

Theoretical concerns with long-term low-dose cyclophosphamide include cumulative bone marrow suppression and bladder toxicity (hemorrhagic cystitis). However, metronomic doses are much lower than conventional high doses, limiting these risks; regular monitoring with complete blood counts and urinalysis is still required.

MC is not suitable for every patient. It may be insufficient alone when aggressive, rapidly growing tumor burden threatens organ function. In such cases, MC is sometimes considered for "maintenance" or a "bridge" role, aiming for disease control rather than cure.

Its Place in Clinical Practice

• Ovarian cancer: stands out for its potential to reasonably prolong PFS while preserving quality of life in platinum-resistant / heavily pretreated patients. Combinations (MC + bevacizumab ± immunotherapy) are the most promising area.
• Metastatic breast cancer: the goal is "long-term stable disease." Adding bevacizumab showed a PFS advantage, but the OS benefit is unclear. The aim is chronic suppression and symptom control rather than aggressive cure. 
• Pancreatic cancer: in patients controlled with first-line treatment, MC-style maintenance may prolong PFS/OS in selected cases and keep toxicity manageable; although data remain early-phase, clinicians increasingly discuss it.

Although MC may be perceived as "milder conventional chemotherapy," strategically it is something quite different: chronic suppressive treatment that inhibits angiogenesis, breaks immune suppression, and biologically wears down the tumor.

The next step is to clarify which sequences and biomarkers make MC most effective with immunotherapies and targeted treatments. In recurrent ovarian cancer, for example, MC + anti-VEGF + anti-PD-1 has shown much higher response rates than chemotherapy alone; this is the real clinical value of targeting the microenvironment. 

Metronomic chemotherapy challenges the cliché "lower dose = less efficacy." Its main goal is slow but continuous tumor suppression, drying up the vascular bed, easing immune suppression, and keeping the patient functioning. Among solid tumors, the strongest current evidence concerns recurrent/platinum-resistant ovarian cancer and later-line metastatic breast cancer patients; maintenance is increasingly discussed in aggressive settings such as pancreatic cancer, where leaving the patient untreated is undesirable.

The clinical message is clear: High doses are not always necessary; in some patients, a "continuous suppression + manageable adverse effects" strategy may be more meaningful for quality of life and progression-free time.

References

1. Wu H et al. Metronomic chemotherapy in cancer treatment: new wine in an old bottle? 2024. (Current review; summarizes the antiangiogenic and immunomodulatory effects of low-dose continuous chemotherapy.) 
2. Mayer EL et al. Randomized phase II study of metronomic cyclophosphamide/methotrexate ± bevacizumab in metastatic breast cancer. Updated 2024 analysis. Adding bevacizumab provided a PFS advantage. 
3. Garcia AA et al. Phase II trial of bevacizumab plus low-dose oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol. 2008; among the first major data showing antitumor activity and tolerable toxicity. 
4. Zsiros E et al. Pembrolizumab + bevacizumab + oral metronomic cyclophosphamide in recurrent ovarian cancer: single-arm phase II. JAMA Oncol. 2021; ORR 47.5%, clinical benefit 95%, median PFS 10 months. 
5. Attianese D et al. Real-life clinical benefit of oral metronomic cyclophosphamide in recurrent ovarian cancer. 2024; ~40-50% clinical benefit reported even in elderly and heavily pretreated patients, well tolerated. 
6. Reni M et al. Metronomic cyclophosphamide maintenance after first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). 2023 analysis; prolonged PFS/OS reported with well-tolerated maintenance. 
7. Khan OA et al. Continuous low-dose cyclophosphamide and methotrexate with celecoxib in advanced solid tumors: antiangiogenic rationale and clinical benefit rates ~%30-40. Br J Cancer. 2011.